The Globe and Mail reports in its Friday, Nov. 10, edition that BMO Capital analyst Stephen MacLeod has reaffirmed his "outperform" recommendation for Dentalcorp Holdings. The Globe's David Leeder writes that Mr. MacLeod gave his share target a $1.50 trim to $11. Analysts on average target the shares at $11.25. Mr. MacLeod says in a note: "Q3/23 results were slightly weaker than expected, but Q4/23E guidance in line; 2023E outlook unchanged: DD revenue and EBITDA growth, with FCF generation to fund deleveraging. We continue to appreciate the recurring characteristics of the Canadian dental market (reflected in stable SPRG), as well as dentalcorp's multi-year opportunity to grow its network of dental clinics. However, we believe progress on 2024E+ margin expansion will be key to moving the stock higher. We see value in the stock (7.9 times 2024 estimated EV/EBITDA vs. 11.2 times peer average), although could see near-term price volatility." The Globe reported on March 25 that Mr. MacLeod rated Dentalcorp "outperform" when it could be had for $9.09. The Globe reported on Oct. 5 that Stifel analyst Justin Keywood had reaffirmed his "buy" call on Dentalcorp Holdings. The shares could then be had for $6.17.